right place portfolio time initi coverag market outperform
initi coverag tela market outperform rate
price target rare one see new medic solut provid signific
benefit essenti constitu patient surgeon facil
payor nutshel tela develop soft tissu
repair proprietari ovitex devic combin strength handl benefit
cheaper option biocompat featur expens altern
lower price point yield new best world answer
view
two fda-clear product aim primarili two larg establish
market model two-year compound-annual-growth-rate sale growth begin
would put compani upper echelon growth name sector
price target base ev/revenu multipl appli
revenu estim mln
note up-front extens histori arena cover
main competitor lifecel part allergan kci latter bought
former manag team whose key member
known year also cover orthovita stryker
mp latter bought former arm med-tech
experi help surgeon input team sought improv sever
surgic repair procedur innov incumb somewhat
stagnant decad pois expand market
proprietari materi process mani biolog product market
today deriv dermi human anim identifi ovin rumen
sheep forestomach excel sourc option extens suppli
importantli multipl layer materi uniqu interwoven
embroid polym pattern creat reinforc matrix sever doctor
refer biolog rebar design intend provid
benefit biolog matric polym plastic materi minim
shortcom importantli compani ip cover sourc materi
develop method isol scaffold chang
biomechan properti caus interweav polym thread
best world typic synthet polym mesh strong easi
handl cheap also associ higher inflammatori
respons higher infect risk lack remodel pure biolog
matric develop address issu gener strong
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
 stretch harder handl expens ovitex intent design
thread proverbi needl address issu includ cost
biolog materi interwoven polym stitch less polym content
synthet mesh limit immunolog respons yield greater strength pure
biolog make easier handl lockstitch embroideri pattern creat rip-stop effect
prevent unravel cut final biolog product offer multipl layer
enhanc function tissu remodel
surgeri hernia repair plastic reconstruct primarili breast reconstruct
market natur benefit biolog competit also establish
area year ago respect tam bln bln importantli
ampl reimburs place make stori one tri succeed better
mousetrap howev opinion chanc success greatli augment
strateg decis price devic discount biolog altern
give surgeon want anoth key differenti set give
custom specif want offer multipl product size design shape
ovitex hernia repair alreadi four version four six eight layer rang
depend size thick choic resorb perman stitch
ldr four layer ellips shape biolog specif design robot
procedur ovitex pr plastic reconstruct three-lay implant come three
shape corner-lock embroideri pattern allow stretch direct
desir option unmatch biolog today like iter ahead
clinic data date support efficaci main goal hernia repair obtain good outcom
limit number recurr explant primat studi bravo studi
ovitex show excel data versu peer zero recurr patient one year
expect addit read-out year come ovitex pr front manag plan
discuss investig devic exempt fda eventu gain specif breast
reconstruct label note product obtain date
concentr account base focal sale forc suffici compet much larger entiti
med-tech challeng even new product featur seem support adopt
importantli top facil perform tela target procedur
manag believ tackl account rep mln new cash
hand manag rapidli hire new rep continu build account open
date
premier growth profil blend rang believ take lot
inroad significantli drive sale needl higher tela initi target market
complex moder ventral/abdomin wall reconstruct mln build busi
alon could support forward estim howev think ovitex potenti
much disrupt even less-compl procedur time due featur
backlash plastic mesh given larger current biolog market size ovitex pr
expect even steeper ramp ahead almost even split sale two line
gross margin remain rang profil could support profit
mln top-lin run rate obtain depend primarili hire model two-
year consolid compound-annual-growth-rate
price target base ev/sal multipl appli revenu estim
mln valuat repres multipl line peer group rapidly-grow medic devic
compani figur given expect notabl year-over-year revenu growth improv
year ahead albeit smaller base believ compani growth profil justifi
ev/sal target multipl note often expand premium compani grow
y/i howev given earli ramp appli believ reason
conservat gate
tela complet initi public offer novemb price compani
issu mln share repres gross rais mln mln net transact fee
cash cash equival mln plan expand commerci effort
hire addit sale rep well fund product clinic research develop order
acceler surgeon adopt top-lin growth
changeci revenu ev/salesrev best world
synthet mesh
handl lower cost
well advantag
tela uniqu proprietari product design combin benefit current commerci offer
simultan address limit categori tandem clear perform
usag advantag ovitex also cheaper biolog resorb competitor
compel hernia repair option hand immin launch ovitex pr product plastic
reconstruct surgeri compani establish valuabl platform technolog provid two
signific shot goal
product differenti address shortfal commerci offer
combin benefit biolog polym plastic materi ovitex reinforc tissu
matrix tela bio main product contain biolog materi util proprietari embroideri
stitch pattern design maintain product durabl integr allow flexibl
rapid tissu integr ovitex offer new categori tissu reinforc provid novel
solut issu sacrif structur strength reduc complic due infect
ovitex interwoven polym increas strength compar biolog materi alon
promot rapid absorpt tissu remodel heal enhanc surgeon handl
physician trim form without unravel shown complic caus
recurr bravo studi thu far patient one-year follow-up
competit price deliv compel econom benefit custom
tela hernia repair platform offer enhanc featur design benefit ovitex
product also intent price lower biolog competitor averag product famili
garner cost save lead biolog matric resorb synthet mesh given
materi use perman synthet mesh product lower up-front cost howev
much higher chanc recurr long-term econom cost patient experi
complic due implant could potenti much signific synthet mesh address
solid grow clinic data
safeti efficaci durabl ovitex demonstr non-human primat data
well compani bravo studi case complet primat tela
product show rapid tissu integr revascular compar biolog
matric addit lower inflammatori respons versu perman resorb synthet
mesh compani also report posit earli data within bravo studi first
patient experienc ventral hernia recurr explant surgic site occurr one-
year follow-up post procedur compar favor biologic/resorb mesh competitor studi
show recurr rate follow-up
establish reimburs larg hernia repair market
oper market well-establish ampl reimburs place hernia repair
code use fix procedur payment system consist lump-sum payment rate base
level complic hernia surgeon paid depend specif code associ
procedur due fixed-pay rate per patient natur reimburs system
incentiv hospit effici treat patient favor cost-effect solut
ovitex
larg adjac opportun plastic reconstruct surgeri come on-line
addit focu hernia market ovitex offer anoth growth
opportun within plastic reconstruct surgeri ovitex pr platform product receiv
fda clearanc april limit launch shortli thereaft may
compani expect fulli launch ovitex pr current clear use
implant reinforc soft tissu patient requir soft tissu repair plastic reconstruct
surgeri look ahead compani intend engag discuss fda regard ide
studi indic breast reconstruct surgeri due product durabl eas
handl flexibl tela bio expans larg area could prove benefici surgeon
patient show estim product offer
figur jmp annual volum sale estim product
two compel
shot goal within
larg hernia repair
way win
view innov player differenti product offer market larg
gone without novel product introduct past sever year believ compani
potenti gain signific traction hernia plastic reconstruct market
valuat invest thesi center belief remain stand-alone publicli
trade go concern acknowledg howev larg player space constantli look
expand portfolio acquisit offer greater growth opportun said
would surpris end crosshair one larg consolid
prsrevenuebi product prsvolum product inc
former research coverag chartnet purchas priced target companytarget symbolacquir companypric medic bardbcrbecton holdingsldrhzimm medicalmrexcelsior union management nashknsyroy conceptskciapax partner capit endovascularmendjohnson cryoboston medicalttgregener incorporateddjor neuromodulationansist jude medic medicalclsrjohnson mln ltm sale inc
offer
materi design
medic technolog firm design develop market new categori
tissu reinforc materi address unmet need soft tissu reconstruct compani
offer portfolio advanc reinforc tissu product hernia repair abdomin wall reconstruct
well plastic reconstruct surgeri within regen medicin market
introduc disrupt solut specif design collabor surgeon
unit implant thu far product display improv clinic outcom
reduc overal cost care report explant relat product
repres fda-clear product use interwoven polym fiber biolog layer
compani portfolio current consist ovitex hernia repair abdomin wall recon product
ovitex pr matrix use plastic reconstruct surgeri offer fda-
clear june april ovitex ovitex pr respect
obtain current held compani exclus manufactur partner aroa biosurgeri
product integr multipl layer minim process biolog materi structur
uniqu interwoven embroid polym pattern make implant custom
product construct materi maintain increas structur integr strength
compar biolog allow necessari degre stretch known complianc replic
load-bear capabl abdomin wall human also promot enhanc product
handl surgeon
tela util high-qual ovin rumen forestomach sheep develop tissu
matric sourc definit licens agreement exclus manufactur
supplier aroa biosurgeri base new zealand partnership give compani low-fixed-cost
raw materi net sale payment contract aroa biosurgeri revenue-shar
arrang abl competit price product without impact gross margin
pass cost save custom
look ahead tela bio strateg goal eventu becom lead provid soft tissu
reconstruct product manag expect pursu focu sever key
oper initi recent infus capit ipo compani expect increas
commerci footprint ad new sale territori end octob hire clinic
develop specialist order drive product adopt larger headcount also support tela
plan pursu surgeon educ effort spread awar ovitex portfolio current
manag expect reach area end believ long-term goal
account manag am would broadli provid adequ coverag total domest market
facil perform hernia plastic reconstruct surgeri tela initi plan
cover top hospit target soft tissu procedur perform
expect compani sale rep could reach mln matur territori given tela focu
high-volum call point overlap gener plastic recon surgeon hospit
run rate could move higher abl reach agreement larg group purchas
organ gpo integr deliveri network idn
go forward compani hope establish contract sever larg gpo idn
would grant greater access high-volum geographi provid priorit statu within hospit
procur depart turn would significantli elev tela product exposur
surgeon drive util larger number hospit
given ovitex cost-sav benefit posit clinic outcom compar offer feel
contract could consid advantag group type focu promot high-
qualiti care econom viabl treatment accord healthcar suppli chain
associ hsca hospit util gpo contract purchas
function hospit purchas made agreement averag
 proceduresmoder ventral inguin hiatalmoder complex ventralcomplex ventral abdomin wall reconstructionovitexovitex inc
figur corpor timelin accomplish upcom catalyst
april found anthoni koblish ceo maarten persenair md commenc aroa agreement exclus licens use ip develop sale product ovitex began commerci novemb announc settlement litig disput lifecel initi bravo studi evalu ovitex treatment ventral hernia complet seri financingnovemb commerci ovitex lpr design use laparoscop robotic-assist surgeri introduc addit size ovitexjanuari first patient treat ovitex europejanuari nora brennan announc cfoapril fda-clear announc ovitex pr plastic reconstruct surgeryjun announc one-year data bravo studynovemb close initi public offer rais gross proce bravo data first initi post-market studi robot ventral hernia repair use ovitex bravo data first patient bravo data first patient potenti full bravo studi data read-out launch longer-act resorb synthet high-strength perman polym beyond inc
ovitex reinforc tissu matrix product famili address hernia repair abdomin
wall reconstruct offer repres uniqu solut within regen medicin
specif engin design combin benefit biolog polym materi give rise
potenti disrupt current continuum care begin domest commerci juli
ovitex fda clear design use sever hernia applic includ
simpl complex ventral hiatal inguin unbil parastom
consist biolog materi interwoven polym ovitex featur sever advantag
exist commerci product minim common shortcom addit ovitex
price competit offer rang size thick make advanc biolog repair
avail broader patient popul
product major
level due structur
integr novel
design advantag
ovitex materi
advantag ovitex
strength durabl complianc given composit synthet mesh use hernia repair
exhibit biomechan strength durabl howev biolog matric demonstr limit
area ovitex design interwoven polym fiber enhanc structur strength
compar biolog offer stronger simultan allow product conform
physiolog complianc properti without over-stretch elong often issu pure
biolog option result compani strength test show ovitex product met
exceed publish data market-lead perman resorb synthet mesh
compani non-human primat studi ovitex display best preserv
origin shape demonstr less contract compar biolog synthet mesh
durabl soft tissu materi use hernia procedur key attribut success
reconstruct degre substanc stretch known complianc also emerg
crucial element given materi must offload tension aris repair
develop product perform tensil test ensur ovitex fell within
complianc requir abdomin wall subject typic anatom load base
find ovitex exhibit complianc differ thick offer fall within
ideal rang nativ abdomin wall structur compani competitor product
adequ meet biomechan complianc target rang make subject excess
figur complianc result tensile-test studi
inflammatori respons infect risk anoth concern hernia repair impact
inflammatori respons due placement foreign bodi given perman synthet mesh
often made plastic complic significantli persist post-surgeri could result
encapsul implant fibrot tissu contract mesh issu aris
promin use synthet reconstruct one main goal biolog option
lessen concern made biolog materi larg surround polym
compon ovitex adequ circumv repercuss bodi potenti neg reaction
foreign materi implant
stretchvert stretchdiagon stretchcompli rang natur human abdomin wall inc
complic associ inflammatori respons includ risk bacteri colon
subsequ infect repair site turn requir addit surgeri remov
impact mesh surround tissu creat risk cost hospit late litig regard
infect impact synthet mesh manufactur amount lawsuit current
pend expect accumul ovitex notabl low polym profil micro-
channel design promot earli cell infiltr tela product reduc potenti infect
seen ovitex bravo studi
soft tissu remodel matric deriv human anim dermi allow patient tissu
replac biolog time mechan known remodel natur biolog
offer promot process perman synthet mesh imped soft tissu regener
tela reinforc tissu matric construct hundr micro-channel enhanc surfac
area permeabl result rapid absorpt wound fluid blood implant
figur enabl improv suppli oxygen cellular infiltr revascular improv
function tissu remodel heal layer help
surgeon handl beyond benefit discuss ovitex also design promot eas use
surgeon product embroideri pattern creat allow trim shape without
unravel polym pliabil flexibl enhanc handl
implant ovitex conform readili contour surgic site sutur tack
easili oper
addit minim invas surgeri repair hernia involv laparoscop robotic-assist
techniqu reduc healthi tissu disrupt increas number given mi
oper util small incis trocar narrow hollow tube biolog product
compat procedur address issu develop ovitex lpr offer
specif tailor use laparoscop robotic-assist surgic hernia repair repres
biolog product abl implant robot product featur element improv
surgic handl includ two extra embroid line enhanc endoscop orient
align introduc bodi variou size trocar port
competit low cost mention ovitex combin strength weak
synthet biolog hernia repair option mark superior product opinion consid
structur physiolog handl featur mind compani strateg
price product portfolio lead biolog matric provid meaning cost save
custom consid multipl clinic use product ovitex competit price could
averag offer cost save lead biolog matric resorb synthet mesh
ovitex pr compani second portfolio product address unmet need plastic
reconstruct surgeri receiv clearanc april use implant reinforc soft
tissu weak exist patient began product limit launch may
full introduct expect direct sale forc similar counterpart use hernia
repair ovitex pr util techniqu weav polym fiber ovin rumen biolog
materi optim product durabl complianc handl
prevail differ compar tela hernia product overarch design compos
allow product stretch maintain shape addit hole die-cut slit facilit
fluid manag promot rapid cellular infiltr creat direct bias stretch use
reconstruct breast surgeri ovitex pr avail variou shape size suit
surgeon prefer also trim desir shape without unravel
exist biolog use plastic reconstruct surgeri impos two major challeng surgeon
high product price excess stretch potenti revis surgeri ovitex pr remedi
issu offer lower cost compar lead biolog competitor util design
maintain structur simultan control degre direct stretch today
surgeon use biolog matric vast major implant-bas breast reconstruct procedur
howev materi well-character clinic literatur recommend
european guidelin techniqu product approv clear fda
specif procedur current indic plastic reconstruct surgeri
broadli commun fda concern potenti protocol studi would
expand indic ovitex pr breast reconstruct surgeri expand indic
ovitex pr could potenti market prosthetic-bas reconstruct restor breast
normal shape appear post-mastectomi
hernia
diseas expand
market huge
possibl assumpt
tela ovitex product famili address hernia abdomin wall reconstruct market
hernia repair one common procedur perform domest estim
million surgeri includ recurr annual condit occur pressur caus organ
intestin fatti tissu push weak point surround muscl caus
pain bulg appear around affect area hernia form sever region bodi
classifi develop protuber commonli develop upper abdomen
ventral around groin inguin instanc occur prior surgic scar site
incision well chest caviti way stomach bulg hiatu toward
esophagu hiatal base size afflict region patient co-morbid
obes diabet histori prior repair potenti degre contamin site
four type hernia vari complex current main treatment ailment
surgic set lump back abdomin wall often reinforc mesh
ensur compromis tissu adequ fortifi
break mln annual surgeri total compris complex/moder
ventral hernia repair simpl ventral case inguin occurr addit
hernia includ hiatal parastom epigastr account combin
procedur specif hiatal treatment annual procedur often use biolog
matric resorb synthet option repres addit mln opportun
million procedur perform year hernia repair current use
type materi perman resorb synthet mesh biolog matric
support repair site mind tela consid total address market
opportun ovitex offer bln base volume-weight averag sell price
product within segment figur
figur hernia address market type
near term plan focu establish product complex/moder ventral given
biolog matric resorb synthet mesh tradit util type
procedur believ clinic benefit structur superior compar lower price
compani ovitex product offer competit advantag within complex moder ventral
abdomin wall reconstruct categori turn prompt meaning penetr
mln market alon simpl ventral inguin case often use cheaper synthet
mesh could see shift toward use product procedur
demonstr benefit complex procedur time potenti side effect inher
use plastic substanc inflammatori respons infect lead recurr surgeri
healthcar provid may opt util product natur mesh order prevent simpl
case becom complex patient impli higher cost given addit surgeri well
increas usag robotic-assist platform ventral inguin procedur tela
expect launch addit sku ovitex lpr line also support compani
integr two market given ovitex product current biolog product
compat robot system expect approach meaning contribut compani
top-lin tela hernia offer use robot addit self-grip ovitex
product develop slate year-end introduct posit address
inguin market opportun
figur intuit surgic gener surgeri growth davinci robot
initi complex focu
long-term opportun
simpl ventral
inguin bolster
gener surgeon elev util minim invas robotic-assist surgeri
evid progress seen market-lead robot compani nc
target ventral inguin hernia repair isrg da vinci platform seen notabl growth case
volum within gener surgeri segment includ hernia colorect cholecystectomi
bariatr grow divis procedur y/i compani note
led hernia repair contribut increment domest growth intuit also
comment hernia repair procedur repres signific opportun potenti drive
growth futur period posit indic curat addit product launch toward
tela bio reinforc tissu matric sold competit hernia market sever larg
player offer synthet biolog resorb mesh product perman synthet option includ
ventralight becton dickinson nc acquisit bard proceed johnson
johnson nc well progrip parietex own nc sinc
categori focus use plastic simpl ventral hernia treatment consid tela primari
competitor offer natur repair product biolog resorb synthet mesh
lead biolog product includ strattic allergan acquisit lifecel gentrix acel
xenmatrix bard primari resorb option includ phasix gore bio-a
tela second portfolio product known ovitex pr reinforc tissu matrix address
plastic reconstruct surgeri market within arena advanc tissu biolog
product allow offer use treat wide varieti applic aesthet
function improv patient affect defect abnorm trauma burn tumor
diseas natur biolog matric shown clinic result valid util surgic
reconstruct chest wall pelvic region extrem breast
current surgic mesh devic includ ovitex pr obtain fda clearanc grant
specif indic use breast surgeri howev surgeon often util biolog matric vast
major prosthet breast implant reconstruct follow remov cancer tissu
mastectomi biolog provid addit support assist defin shape
affect area revascular properti allow tissu integr mastectomi
procedur either unilater remov one breast bilater remov breast
expans ide
addit advantag
repres surgeri respect
domest procedur perform relat breast reconstruct
surgeri relat plastic recon indic also undergon base current sale
biolog base product use plastic reconstruct surgeri market compani estim total
address market mln within plastic reconstruct surgeri market
alloderm primari competitor
annual rate new breast cancerscas countrat per peopl inc
figur alloderm ovitex pr
compani intend file investig devic exempt protocol studi fda
examin safeti efficaci ovitex pr product line mind view breast
reconstruct market potenti meaning opportun bolster ovitex prss
advantag design price point compar market-lead biolog offer exist product
prone excess stretch time tela matrix maintain structur allow
amount direct complianc order effect shape contour breast non-
human primat trial ovitex pr also demonstr rapid cell infiltr faster
remodel compar biolog materi current use market
broadli breast reconstruct transit pre-pector sub-pector procedur could
offer benefit use natur repair product sub-pector surgic techniqu
upper portion implant place pectorali muscl biolog matrix place
around lower portion prosthet pre-pector entir implant fix
muscl top surfac cover requir larger biolog matrix compar sub-pector
given tissu need former surgeri market could see increas demand
shift procedur
demand product
ovitex pr
tela plan continu build portfolio clinic evid ovitex product order
demonstr safeti efficaci hernia repair abdomin wall reconstruct
compani current sponsor single-arm prospect studi bravo evalu outcom
patient treat ovitex open laparoscop robotic-assist complex ventral hernia
procedur goal studi compar perform ovitex biolog
synthet devic primari endpoint measur incid earli post-op surgic site
occurr wound-rel event enrol patient complet june
compani releas one-year outcom first particip show recurr
rate use tela product compar favor result seen competit
patient progress post-oper manag plan publish
follow-up result bravo studi next sever year also track health
econom outcom within trial
product tissu materialhernia recurr ratenumb hernia recurrencenumb patient complet follow-upfollow-up period monthsphasixresorb synthet synthet synthet tissu inc
addit bravo studi ovitex evalu non-human primat two
product configur compar five commerci avail resorb synthet mesh
biolog matric subject evalu week sign herniat
inflamm adhes contract abnorm length width
graft also measur week ovitex show best preserv structur
minim inflamm demonstr rapid cellular infiltr vascular graft fulli
remodel host tissu notabl faster synthet biolog use contrari
result seen ovitex biolog matric week contract significantli length width
show slower cellular infiltr vascular hand resorb synthet
display mild-to-moder inflamm persist throughout studi perman synthet
exhibit high degre length width contract similar amount inflamm
tela plastic reconstruct product evalu non-human primat
compar alloderm week interv studi observ differ
inflammatori respons cellular infiltr qualiti remodel tissu materi
product inflammatori respons minim howev two ovitex pr show
less respons throughout observ period compani matrix demonstr earli
infiltr due highli permeabl natur promot host cell infiltr within collagen
network compar alloderm product show tissu remodel ovitex pr slightli
ahead process time point versu competit devic tela product
maintain structur alloderm significantli contract week order pursu
indic breast reconstruct surgeri manag plan engag fda regard
 data patient data patient data patients- data patients- data patients- data inc
within hernia repair market payment code implant biolog matric synthet
mesh well-establish give tela product clear reimburs payment system
ms-drg medicar sever diagnosi relat group consist lump-sum rate vari base
degre procedur complic comorbid patient nation averag
payment hernia procedur except inguin femor depend
surgeri specif figur product-specif reimburs advantag exist within
hernia repair rather gener code implant mesh current use
reimburs system encourag hospit util effici treatment given fixed-r natur
benefit variou advantag ovitex offer especi lower price point earli
clinic data reveal decreas rate recurr allow hospit optim margin
incentiv hospit
solut ovitex
medicar physician fee schedul inpati outpati data
third-parti payer often make coverag decis data demonstr specif product
efficaci well econom benefit compani bravo studi continu progress
alreadi shown posit earli outcom patient treat ovitex manag expect
gather addit cost-sav analysi result believ tela portfolio tissu matric
repres cost-effect solut greatli reduc risk inher hernia repair surgeri
turn plastic reconstruct industri reimburs procedur vari in-
patient out-pati market in-pati payment polici similar hernia establish
drgdescript nation average drg procedur except inguin femor w/ procedur except inguin femor w/ procedur except inguin femor w/o major complic comorbod cc complic comorbiditiessurgeon initi incision ventral hernia initi incision ventral hernia incarcer recurr incicion ventral recurr incicion ventral hernia incarcer mesh prosthesi open incision ventral hernia repair mesh closur debrid necrot soft tissu infect lsit seper addit code incision ventral average medicar paymentdescript inc
drg present specif product advantag exist howev major implant-bas
reconstruct surgeri perform out-pati set also maintain procedur coverag
arena reimburs advantag specif product exist depend facil
payer challeng predict coverag develop tela plastic recon product
given rate negoti facil level ovitex pr competit price compar
offer think abl demonstr econom valu third-parti payer
addit benefici idiosyncrasi advantag could becom appar
compani continu invest clinic evid ovitex pr product famili
anoth pillar tela oper strategi expand commerci reach invest
direct sale forc octob compani sale territori expect
on-board addit account manag am key geographi order drive adopt revenu
current manag expect reach area end full-year believ
long-term goal am would broadli provid adequ coverag total domest market
addit region account manag compani also util busi manag focus
contract implement drive suppli chain relationship clinic develop
specialist concentr kol develop clinic educ within territori
approxim facil perform hernia plastic reconstruct surgeri initi plan
cover top hospit target soft tissu procedur perform
expect compani sale rep could reach mln matur territori given compani
focu high-volum call point overlap gener plastic recon surgeon
hospit sale forc product could move higher abl reach agreement larg
group purchas organ gpo integr deliveri network idn compani hope
establish contract sever gpo idn would grant greater access high-volum
geographi greatli elev tela product exposur surgeon potenti improv util
larger number hospit
cost-sav benefit posit clinic outcom ovitex compar offer
believ contract could consid advantag group type focu
promot high-qual care econom viabl treatment accord healthcar suppli
chain associ hsca hospit util gpo contract purchas
function hospit purchas made agreement averag
compani plan invest drive surgeon awar expand brand relationship
product reach educ program like novel offer establish surgeon adopt
educ crucial product success plan increas awar ovitex
exhibit symposium also public addit clinic data demonstr
anoth crucial advantag potenti commerci success tela compani
manufactur suppli agreement partner aroa biosurgeri long-term licens aroa
grant tela exclus suppli ovin rumen manufactur variou ovitex hernia
plastic reconstruct product grant exclus develop commerci right north
america eu norway switzerland russia two compani enter agreement
amend restat juli initi term licens termin
latter august expir last patent cover bovin ovin product
current juli also option attach allow extens addit ten-
year period ovin rumen optim collagen structur biomechan profil cellular
infiltr plenti suppli agreement offer compani low cost good fix
net sale promot barrier entri potenti new soft tissu matric given
sourc materi cheapli
current aroa manufactur product singl locat auckland new zealand
give rise risk supply-chain disrupt natur disast similar occurr
compani intend establish redund product facil lessen exposur suppli risk
certain circumst may engag replac contract manufactur temporarili
allevi potenti failur aroa meet demand compani product present aroa
capabl meet tela manufactur demand howev adopt improv capac limit
may eventu appear would requir aroa expand abil produc higher quantiti
plan state alreadi consid
clearanc tela product ovitex ovitex pr obtain
current held aroa mean compani partner subject agenc regul
respons maintain complianc qualiti standard applic fda requir
relat ovitex portfolio aroa facil auckland new zealand fda regist iso
tela intellectu properti appli compani differenti product design construct
raw materi cover method interweav polym thread biolog matrix
compani also reli partnership intellectu properti licens aroa biosurgeri
agreement allow aroa develop tela product util licens ip mandat
make payment mln conting revenue-bas mileston
octob exclus licens two issu patent expir
compani own six issu allow patent expir
six pend patent applic project expir
intern tela also own four non-u patent applic expect expir
maintain exclus licens patent europ canada expir
antoni koblish presid ceo tela sinc co-found compani april
tenur also serv compani board director mr koblish bring
wealth knowledg compani year experi within healthcar industri
specif regen medicin market prior time mr koblish
presid ceo orthovita inc acquir mp
time grew compani valuat mln mln sale mr
koblish co-found onko surgic oncolog compani current serv chairman
board earn bachelor scienc degre mechan engin worcest
polytechn institut receiv master scienc engin degre mechan
engin appli mechan univers pennsylvania
nora brennan serv compani cfo sinc januari brine year financi
experi compani ms brennan previous held cfo posit
specialti pharmaceut compani prior join compani ms brennan employ
integra lifesci held variou leadership role includ time senior vice presid
investor relat corpor treasur also previous work jp morgan
variou financ invest bank role ms brennan earn bachelor degre
univers illinoi receiv mba univers chicago booth school busi
dr maarten persenair one compani co-found serv compani chief
medic offic sinc decemb prior time orthovita
alongsid antoni koblish facilit compani clinic effort includ
file fda-id studi vertebr fractur well dr persenair receiv medic
degre groningen univers netherland
dr skott greenhalgh tela sinc bring nearli year experi
develop manufactur medic devic includ cardiovascular gener surgic
orthoped arena product dr greenhalgh earn bachelor degre mechan
engin drexel univers receiv phd fiber polym scienc
master degre textil engin north carolina state univers
stuart henderson vice-president market corpor develop
stuart henderson firm sinc april time assum commerci
busi develop respons previous mr henderson employ quaker partner
healthcar ventur capit fund help secur seri financ tela mr
henderson subsequ transit full-tim prior role quaker partner focus
conduct due dilig medic devic biotech sector mr henderson receiv
bachelor degre biolog scienc cornel univers
calendar year mln except per share data total gross profit sale gener oper profit interest expens expens incom incom loss incom tax expense/ benefit tax net incom ex oper ep ex analysisreport net report epsbas share adjust dilut share sale profit ebit n/an/an/an/an/an/an/an/an/an/an/an/an/aincom loss taxn/an/an/an/an/an/an/an/an/an/an/an/an/aoper net incomen/an/an/an/an/an/an/an/an/an/an/an/an/a inc
medic technolog compani design develop market new categori tissu reinforc materi
address unmet need soft tissu reconstruct compani offer portfolio advanc reinforc tissu product hernia repair
abdomin wall reconstruct well plastic reconstruct surgeri innov solut integr multipl layer minim
process biolog materi uniqu interwoven embroid polym pattern creat reinforc tissu matrix singl direct
sale forc compani market ovitex portfolio hernia repair abdomin wall reconstruct well ovitex pr plastic
reconstruct product princip unit state found began commerci product
profit histor report signific oper loss compani expect continu look forward given
compani annual oper loss outlook impli cash burn associ bottom line may need rais addit fund
futur
third-parti risk tela exclus manufactur contract aroa biosurgeri offer compani consist qualiti low-cost raw
materi agreement promot amount risk aroa sole manufactur supplier ovitex product
reli upon compani heavili meet demand compani partner could potenti experi development/manufactur problem
capac constraint delay product would ultim impact tela busi
product adopt guarante physician adopt ovitex ovitex pr continu expand compani
still earli commerci product invest build sale forc develop product awar
necessari order promot signific adopt ovitex product given competit landscap hernia plastic
reconstruct surgeri market product usag hospit penetr could take longer anticip
regulatori risk compani product subject extens regul intern potenti futur product
introduct need receiv clearanc may requir pma approv prior commerci compani
guarante receiv tela ovitex ovitex pr product receiv fda clearanc howev product
upgrad modif may requir addit clearanc
